Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: A retrospective study in patients with MRSA infections

Kazuaki Matsumoto, Naoko Kanazawa, Kazuro Ikawa, Tomohide Fukamizu, Akari Shigemi, Keiko Yaji, Yoshihiro Shimodozono, Norifumi Morikawa, Yasuo Takeda, Katsushi Yamada

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

An initial loading procedure has been recommended to enable teicoplanin to promptly reach an effective serum concentration for the treatment of methicillinresistant Staphylococcus aureus (MRSA). This study aimed to retrospectively evaluate the pharmacokinetics and pharmacodynamics of teicoplanin to determine the therapeutic target for the teicoplanin trough concentration and an appropriate dosing method during the first 3 days. The mean trough concentrations were 13.2 mg/L for patients with eradication of MRSA. Moreover, logistic regression analysis showed that the teicoplanin trough concentration was 13 mg/L to achieve MRSA eradication with a probability of 89.0%. The rates of achieving ≥13 mg/L in ≤24, 24-36 and ≥36 mg/kg (total dose during the first 3 days) groups were 9.1, 48.4 and 87.5%, respectively. These results suggest that the administration of ≥36 mg/kg during the first 3 days is appropriate to promptly obtain a trough concentration target of ≥13 mg/L for the initial treatment of MRSA infections.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalJournal of Infection and Chemotherapy
Volume16
Issue number3
DOIs
Publication statusPublished - 2010 Jun
Externally publishedYes

Keywords

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Teicoplanin
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: A retrospective study in patients with MRSA infections'. Together they form a unique fingerprint.

  • Cite this